公开(公告)号：US20150198590A1

公开(公告)日：2015-07-16

申请号：US14411496

申请日：2013-07-08

Applicant: Randox Laboratories Ltd.

Inventor： Maria Zellner ,  Ellen Umlauf

IPC: G01N33/53

CPC classification number: G01N33/5308 ,  G01N33/6896 ,  G01N2333/4712 ,  G01N2800/2814 ,  G01N2800/2821

Abstract: The present invention provides an in vitro method to aid the diagnosis of Alzheimer's disease (AD) or Mild Cognitive Impairment (MCI), comprising determining the level of expression of one or more tropomyosin isoform(s) corresponding to P09493-3 and/or P09493-1 in a patient's sample. A kit comprising probes that bind to tropomyosin isoforms P09493-3 and P09493-1 is also provided

Abstract translation: 本发明提供了一种有助于诊断阿尔茨海默病（AD）或轻度认知障碍（MCI）的体外方法，其包括确定对应于P09493-3和/或P09493的一种或多种原肌球蛋白同种型的表达水平 -1在患者的样品中。 还提供了包含结合原肌球蛋白异构体P09493-3和P09493-1的探针的试剂盒

公开(公告)号：US20150073820A1

公开(公告)日：2015-03-12

申请号：US14478437

申请日：2014-09-05

Applicant: RANDOX LABORATORIES LTD.

Inventor： DAVID MCENEANEY

IPC: G06F19/00

CPC classification number: G16H50/20 ,  G16H50/30

Abstract: The current invention enables a method to improve early diagnosis and risk stratification of AMI in patients presenting with chest pain. A quick and accurate diagnosis/risk stratification means that high risk patients can be assigned to the appropriate treatment pathway and low risk patients can be reassured that they have not suffered an AMI and alternative causes of chest pain can be investigated. The method of the present invention is based on the outcome of three factors determined on admission; Electrocardiogram, cardiac troponin level and H-FABP level. Dependent on the results of these three tests the subject can be placed into an appropriate risk category for an AMI having recently occurred and the appropriate treatment pathway can be initiated.

Abstract translation: 本发明使得能够改善患有胸痛的患者中AMI的早期诊断和风险分层的方法。 快速，准确的诊断/风险分层意味着高风险患者可以分配到适当的治疗途径，低风险患者可以放心，他们没有遭受AMI，可以调查胸痛的其他原因。 本发明的方法是基于入院确定的三个因素的结果; 心电图，心肌肌钙蛋白水平和H-FABP水平。 根据这三项测试的结果，可将受试者置于最近发生的AMI的适当风险类别中，并可开始适当的治疗途径。

公开(公告)号：US20140336283A1

公开(公告)日：2014-11-13

申请号：US14367510

申请日：2012-12-21

Applicant: RANDOX LABORATORIES LTD.

Inventor： Sophie Visvikis-Siest ,  Said El Shamieh ,  Helena Murray ,  John Lamont ,  Peter Fitzgerald

IPC: C12Q1/68

Abstract: The invention describes epistatic interactions between single nucleotide polymorphisms on genes associated with blood pressure and provides an application for their use in a method to determine an individual's susceptibility to hypertension and hence whether anti-hypertensive treatment will be beneficial for said individual. In addition gene expression levels are also linked to blood pressure and may also be used to determine susceptibility to hypertension.

Abstract translation: 本发明描述了与血压相关的基因的单核苷酸多态性之间的上位相互作用，并提供了其在确定个体对高血压易感性的方法中的应用，因此抗高血压治疗是否对所述个体有益。 此外，基因表达水平也与血压相关，也可用于确定对高血压的易感性。